Mitoxantron Accord (Mitoxantrone)

Mitoxantrone intercalates into DNA and blocks the activity of topoisomerase II, an enzyme required for DNA unwinding during replication. By preventing DNA strand re‑ligation, the drug induces double‑strand breaks, leading to apoptosis of rapidly dividing cancer cells while sparing most normal tissues.

The dosage of Mitoxantron Accord is individualized and determined by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and cardiac function, and treatment protocol. Healthcare professionals adjust the dose to balance efficacy with safety.

Data on mitoxantrone use during pregnancy and lactation are limited. Because the drug can cross the placenta and may cause fetal harm, it is generally avoided unless the potential benefit justifies the risk. Breastfeeding is not recommended while receiving treatment.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity and submit the request. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mitoxantrone belongs to the anthracenedone class, similar to drugs such as doxorubicin and etoposide. Compared with etoposide, mitoxantrone has a longer intracellular half‑life and may cause less severe nausea but carries a higher risk of cardiotoxicity. Choice of therapy depends on tumor type, prior treatment history and patient comorbidities.

Mitoxantron Accord must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If a temporary temperature excursion occurs, consult the product’s stability data before use.

The product is supplied as an intravenous solution and is administered by slow infusion through a peripheral or central line under the supervision of qualified medical staff. Infusion duration and rate are prescribed by the oncologist and may be adjusted according to patient tolerance and cardiac monitoring results.

The most critical adverse events include cardiotoxicity (reduced left‑ventricular function), secondary acute myeloid leukemia, severe myelosuppression leading to infections or bleeding, hepatic toxicity, and pulmonary fibrosis. Patients should undergo regular cardiac imaging, blood counts and liver function tests throughout therapy.

Mitoxantron Accord is contraindicated in patients with known hypersensitivity to mitoxantrone or any formulation component, those with severe pre‑existing cardiac dysfunction (e.g., ejection fraction < 50 %), uncontrolled active infections, and individuals who are pregnant unless the therapeutic benefit outweighs the risk.